TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today ...
Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma
TORONTO and SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today ...
TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that ...
TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced a ...
Catalent and Triphase Accelerator Corporation have announced that Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been ...
Celgene, already heavily involved with the biotech, has announced a deeper tie-up with private co Triphase Accelerator that sees it buy into its proteasome inhibitor. Under the deal, financial details ...
Dr Shrilakshmi Desiraju, the co-founder of pharmaceutical research and development startup Triphase, exemplifies all the qualities essential in an entrepreneur. In this conversation with YourStory ...
Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results